Kirsten Drejer

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

24 documents for Kirsten Drejer

- SYMPHOGEN Raises [euro]100 Million in Private Equity Round; Novo A/S Leads Round.
...Kirsten Drejer, PhD., Symphogen Chief Executive Officer, c...
- Business Wire
- January 06, 2011
- Symphogen Names New Chief Scientific/Medical and Business Officers.
...Kirsten Drejer, PhD., Symphogen Chief Executive Officer, c...
- Business Wire
- April 15, 2011
- Symphogen Receives US Patent on Lead Cancer Compound Sym004.
...According to Kirsten Drejer, Ph.D., Chief Executive Officer of Symphoge...
- Business Wire
- March 07, 2011

- Symphogen Announces Publication in Molecular Biotechnology of Sympress [TM] II Production System Allowing Single-Batch Recombinant Polyclonal Antibody Manufacturing.
... antibody manufacturing," stated Kirsten Drejer, M.Sc. and Ph.D., Chief Executive Officer o...
- Business Wire
- April 26, 2010
- Symphogen Announces Initiation of Phase 1/2 Trial of Sym004 in Patients with Advanced Solid Tumors in the US.
... this compound into the clinic," stated Kirsten Drejer, M.Sc. and Ph.D., Chief Executive Officer o...
- Business Wire
- April 01, 2010
- Symphogen Appoints Adriann Sax Chief Business Officer.
... point in our company's evolution," said Kirsten Drejer, Ph.D., CEO of Symphogen. . Ms. Sax added, ...
- Business Wire
- August 17, 2009
- Symphogen Appoints Christian Meyer Vice President of Clinical Development.
..., as well as from academia," said Kirsten Drejer, Ph.D, CEO of Symphogen. "His understanding...
- Business Wire
- November 07, 2006
- Symphogen Issued Patent Covering Sympress(TM) Technology for Manufacturing Recombinant Polyclonal Antibodies.
...Kirsten Drejer, Ph.D., Chief Executive Officer of Symphoge...
- Business Wire
- September 11, 2006
- Symphogen and Origen Collaborate to Produce Transgenic Chicken for Generation of Fully Human Antibody Therapeutics.
... as those for infectious diseases," said Kirsten Drejer, Ph.D., CEO of Symphogen. "The transgenic c...
- Business Wire
- March 06, 2009
- Symphogen Enters into Strategic Collaboration with Genentech for Antibody Therapeutics in Infectious Disease.
... and expression technologies," said Kirsten Drejer, Ph.D., CEO of Symphogen. "This deal unders...
- Business Wire
- June 10, 2008